<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38028335</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2059-8661</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of clinical and translational science</Title><ISOAbbreviation>J Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>From a decentralized clinical trial to a decentralized and clinical-trial-in-a-box platform: Towards patient-centric and equitable trials.</ArticleTitle><Pagination><StartPage>e236</StartPage><MedlinePgn>e236</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e236</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/cts.2023.629</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVE" NlmCategory="UNASSIGNED">Despite the intuitive attractiveness of bringing research to participants rather than&#xa0;making them come to central study sites, widespread decentralized enrollment has not been common in clinical trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The need for clinical research in the context of the COVID-19 pandemic, along with innovations in technology, led us to use a decentralized trial approach in our Phase 2 COVID-19 trial. We used real-time acquisition and transmission of health-related data using home-based monitoring devices and mobile applications to assess outcomes. This approach not only avoids spreading COVID-19&#xa0;but it also can support inclusion of participants in more diverse socioeconomic circumstances and in rural settings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our team developed and deployed a decentralized trial platform to support patient engagement and adverse event reporting. Clinicians, engineers, and informaticians on our research team developed a Clinical-Trial-in-a-Box tool to optimally collect and analyze data from multiple decentralized platforms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Applying the decentralized model in Long COVID, using digital health technology and personal devices integrated with our telehealth platform, we share the lessons learned from our work, along with challenges and future possibilities.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dulko</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0274-1657</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Manlik</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palm</LastName><ForeName>Marisha E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-9760-7196</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinquart</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selker</LastName><ForeName>Harry P</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0001-5322-7178</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Transl Sci</MedlineTA><NlmUniqueID>101689953</NlmUniqueID><ISSNLinking>2059-8661</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Decentralized</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">recruitment</Keyword><Keyword MajorTopicYN="N">remote research data acquisition</Keyword><Keyword MajorTopicYN="N">telehealth platform</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38028335</ArticleId><ArticleId IdType="pmc">PMC10663768</ArticleId><ArticleId IdType="doi">10.1017/cts.2023.629</ArticleId><ArticleId IdType="pii">S2059866123006295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahman S, Majumder MA, Shaban SF, et al. Physician participation in clinical research and trials: issues and approaches. Adv Med Educ Pract. 2011;2:85&#x2013;93. doi: 10.2147/AMEP.S14103.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/AMEP.S14103</ArticleId><ArticleId IdType="pmc">PMC3661249</ArticleId><ArticleId IdType="pubmed">23745079</ArticleId></ArticleIdList></Reference><Reference><Citation>Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. At what cost to clinical trial enrollment? a retrospective study of patient travel burden in cancer clinical trials Oncologist. 2018;23(10):1242&#x2013;1249. doi: 10.1634/theoncologist.2017-0628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2017-0628</ArticleId><ArticleId IdType="pmc">PMC6263122</ArticleId><ArticleId IdType="pubmed">29700209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AR, Sun V, George K, et al. Barriers to participation in therapeutic clinical trials as perceived by community oncologists. JCO Oncol Pract. 2020;16(9):e849&#x2013;e858. doi: 10.1200/JOP.19.00662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JOP.19.00662</ArticleId><ArticleId IdType="pmc">PMC7489483</ArticleId><ArticleId IdType="pubmed">32240068</ArticleId></ArticleIdList></Reference><Reference><Citation>De Brouwer W, Patel CJ, Manrai AK, Rodriguez-Chavez IR, Shah NR. Empowering clinical research in a decentralized world. NPJ Digital Medicine. 2021;4(1):102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249659</ArticleId><ArticleId IdType="pubmed">34211085</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolaros M, Babaian D, Corneli A, et al. Regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the clinical trials transformation initiative. Ther Innov Regul Sci. 2020;54(4):779&#x2013;787. doi: 10.1007/s43441-019-00006-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-019-00006-4</ArticleId><ArticleId IdType="pmc">PMC7362888</ArticleId><ArticleId IdType="pubmed">32557302</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Norman GA. Decentralized clinical trials: the future of medical product development?&#x2217;. JACC Basic Transl Sci. 2021;6(4):384&#x2013;387. doi: 10.1016/j.jacbts.2021.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2021.01.011</ArticleId><ArticleId IdType="pmc">PMC8093545</ArticleId><ArticleId IdType="pubmed">33997523</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Ana-Tellez Y, Lagerwaard B, de Jong AJ, et al. Decentralised, patient-centric, site-less, virtual, and digital clinical trials? from confusion to consensus. Drug Discov Today. 2023;28(4):103520. doi: 10.1016/j.drudis.2023.103520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2023.103520</ArticleId><ArticleId IdType="pubmed">36754144</ArticleId></ArticleIdList></Reference><Reference><Citation>
Food and Drug Administration, Center for Drug Evaluation and Research. CDER 2021 Guidance Agenda: New &amp; Revised Draft Guidance Documents, (https://www.fda.gov/media/134778/download) Accessed March 23, 2023.</Citation></Reference><Reference><Citation>National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation. In: Shore C, Gee AW, Wizemann T (eds.) Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop. Washington (DC): National Academies Press (US), 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34752026</ArticleId></ArticleIdList></Reference><Reference><Citation>
ACRO. Decentralizing Clinical Trials: A New Quality-by-Design, Risk-Based Framework. Published online 2020, (https://www.acrohealth.org/dctwhitepaper/) Accessed March 26, 2023.</Citation></Reference><Reference><Citation>Shakeri Hossein Abad Z, Kline A, Sultana M, et al. Digital public health surveillance: a systematic scoping review. NPJ Digit Med. 2021;4(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930261</ArticleId><ArticleId IdType="pubmed">33658681</ArticleId></ArticleIdList></Reference><Reference><Citation>
Winslow, J. The Pew Charitable Trusts. America&#x2019;s Digital Divide. 2019, (https://www.pewtrusts.org/en/trust/archive/summer-2019/americas-digital-divide). Accessed March 23, 2023</Citation></Reference><Reference><Citation>Fu S, Gerber DE, Beg MS. Decentralized clinical trials in oncology: are we ready for a virtual-first paradigm? J Clin Oncol. 2023;41(2):181&#x2013;185. doi: 10.1200/JCO.22.00358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.00358</ArticleId><ArticleId IdType="pmc">PMC9839231</ArticleId><ArticleId IdType="pubmed">35994691</ArticleId></ArticleIdList></Reference><Reference><Citation>Wix SN, Nieva JJ. COVID-19 and the acceleration toward remote cancer care. Proc (Bayl Univ Med Cent). 2021;35(2):259&#x2013;260. doi: 10.1080/08998280.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2021</ArticleId><ArticleId IdType="pmc">PMC8865276</ArticleId><ArticleId IdType="pubmed">35261474</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead DC, Mehrotra A. The growing phenomenon of &#x201c;Virtual-first. Primary Care JAMA. 2021;326(23):2365&#x2013;2366. doi: 10.1001/jama.2021.21169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.21169</ArticleId><ArticleId IdType="pubmed">34807253</ArticleId></ArticleIdList></Reference><Reference><Citation>Daudelin DH, Brewer SK, Cabrera AB, Dulko D, Selker HP. Participant and research team perspectives on the conduct of a remote therapeutic COVID-19 clinical trial: a mixed methods approach. J Clin Transl Sci. 2022; 6(1):e69. doi: 10.1017/cts.2022.397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cts.2022.397</ArticleId><ArticleId IdType="pmc">PMC9257771</ArticleId><ArticleId IdType="pubmed">35836793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns DM, Dulko D, Griffiths JK, et al. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 respiratory viral clearance, viral shedding, and duration of symptoms among patients with mild to moderate COVID-19: a Phase 2 Randomized clinical trial. JAMA Netw Open. 2022;5(2):e2144942. doi: 10.1001/jamanetworkopen.2021.44942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.44942</ArticleId><ArticleId IdType="pmc">PMC8829666</ArticleId><ArticleId IdType="pubmed">35138402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirel LB, Resnick DM, Aram J, Cox CS. A methodological assessment of privacy preserving record linkage using survey and administrative data. Stat J IAOS. 2022; 38(2):413&#x2013;421. doi: 10.3233/sji-210891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/sji-210891</ArticleId><ArticleId IdType="pmc">PMC9335262</ArticleId><ArticleId IdType="pubmed">35910693</ArticleId></ArticleIdList></Reference><Reference><Citation>Olden M, Holle R, Heid IM, Stark K. IDGenerator: unique identifier generator for epidemiologic or clinical studies. BMC Med Res Methodol. 2016;16(1):120. doi: 10.1186/s12874-016-0222-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0222-3</ArticleId><ArticleId IdType="pmc">PMC5024489</ArticleId><ArticleId IdType="pubmed">27628043</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Selker HP, Cohen T, D'Agostino RB, et al. A useful and sustainable role for N-of-1 trials in the healthcare ecosystem. Clin Pharmacol Ther. 2022;112(2):224&#x2013;232. doi: 10.1002/cpt.2425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2425</ArticleId><ArticleId IdType="pmc">PMC9022728</ArticleId><ArticleId IdType="pubmed">34551122</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins CH, Schindler SE, Morris JC. Addressing health disparities among minority populations: why clinical trial recruitment is not enough. JAMA Neurol. 2020;77(9):1063&#x2013;1064. doi: 10.1001/jamaneurol.2020.1614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1614</ArticleId><ArticleId IdType="pmc">PMC7983552</ArticleId><ArticleId IdType="pubmed">32539100</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodson N, Wicks P, Morgan J, Hashem L, Callinan S, Reites J. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit Med. 2022;5(1):58. doi: 10.1038/s41746-022-00603-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-022-00603-y</ArticleId><ArticleId IdType="pmc">PMC9072305</ArticleId><ArticleId IdType="pubmed">35513479</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RKJ, Wu D, Day S, et al. Digital approaches to enhancing community engagement in clinical trials. NPJ Digit Med. 2022;5(1):37. doi: 10.1038/s41746-022-00581-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-022-00581-1</ArticleId><ArticleId IdType="pmc">PMC8956701</ArticleId><ArticleId IdType="pubmed">35338241</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa C, Marsch LA, Winstanley EL, Brunner M, Campbell ANC. Using digital technologies in clinical trials: current and future applications. Contemp Clin Trials. 2021;100:106219. doi: 10.1016/j.cct.2020.106219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2020.106219</ArticleId><ArticleId IdType="pmc">PMC8734581</ArticleId><ArticleId IdType="pubmed">33212293</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyser ND, Marcus GM, Beatty AL, Olgin JE, Pletcher MJ. Digital platforms for clinical trials: the eureka experience. Contemp Clin Trials. 2022;115:106710. doi: 10.1016/j.cct.2022.106710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2022.106710</ArticleId><ArticleId IdType="pubmed">35183763</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;Wrapped&#x201d;: A year in review across our research platforms. Scripps Research Digital Trials Center. December 14, 2022, (https://digitaltrials.scripps.edu/scripps-research-digital-trials-center-wrapped-a-year-in-review-across-our-research-platforms/) Accessed June 26, 2023.</Citation></Reference><Reference><Citation>
Building Better Clinical Trials: A Case Study Exchange. ETH Zurich. 2020, (https://connects.ctti-clinicaltrials.org/show/50) Accessed June 26, 2023.</Citation></Reference><Reference><Citation>DiMasi JA, Smith Z, Oakley-Girvan I, et al. Assessing the financial value of decentralized clinical trials. Ther Innov Regul Sci. 2023;57(2):209&#x2013;219. doi: 10.1007/s43441-022-00454-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-022-00454-5</ArticleId><ArticleId IdType="pmc">PMC9473466</ArticleId><ArticleId IdType="pubmed">36104654</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahne J, Hawk LW Jr. Health equity and decentralized trials. JAMA. 2023;329(23):2013&#x2013;2014. doi: 10.1001/jama.2023.6982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.6982</ArticleId><ArticleId IdType="pubmed">37261810</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess KE, Price LL, King R, et al. Development and validation of a multivariable model and online decision-support calculator to aid in preoperative discrimination of benign from malignant splenic masses in dogs. J Am Vet Med Assoc. 2021;258(12):1362&#x2013;1371. doi: 10.2460/javma.258.12.1362.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/javma.258.12.1362</ArticleId><ArticleId IdType="pmc">PMC8908434</ArticleId><ArticleId IdType="pubmed">34061606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>